Q: What is the consensus Q1 and operating ebitda?
You can view 3 more answers this month. Sign up for a free trial for unlimited access.
Investment Q&A
Not investment advice or solicitation to buy/sell securities. Do your own due diligence and/or consult an advisor.
Q: Hi guys, in a previous answer today you stated that gud is worth a 5% holding within a portfolio, what about pli? I have them both equal inside my portfolio (balance), should I lighten up on pli and drop down to a 3% and bump up gud to 7% ?
Thanks
Jim
Thanks
Jim
Q: Hi 5i Team,
Is it still okay to purchase CXR at today's closing price. I know the downside if the sale does not go through, but what is the upside if it does go through.
As always, thanks for your great service.
Ivan
Is it still okay to purchase CXR at today's closing price. I know the downside if the sale does not go through, but what is the upside if it does go through.
As always, thanks for your great service.
Ivan
Q: Two questions.Both ntb and hsm have moved the last few days helped by some hype.The president of hsm is scheduled,I think,on Bnn this afternoon.Your opinion of these companies is appreciated.
Q: Hello 5i,
One of my 'fun to own' companies is having both good news and bad news. The CEO just left (bad) and the company is reporting good news on an open trial with just 10 people taking voclosporin, they also have been given fast track designation. The company un-blinds their larger trial (phase 2b) this August. What do you think of all this, is worth holding for the binary event?
Thanks,
One of my 'fun to own' companies is having both good news and bad news. The CEO just left (bad) and the company is reporting good news on an open trial with just 10 people taking voclosporin, they also have been given fast track designation. The company un-blinds their larger trial (phase 2b) this August. What do you think of all this, is worth holding for the binary event?
Thanks,
Q: Do you have thoughts about the new CEO? Does this change the fundamental outlook for Valeant in the short to medium term? Thank-you
Q: With CXR paying its dividend in US dollars, do you think a bid for the company would be in US or Canadian dollars? Thanks!
Linda
Linda
Q: Greetings, Peter and Co.
I currently have 14.8% of my investments, excluding real estate and bullion, in the biotech/healthcare sector. I hold
Biosyent (RX) 0.5% (I have a considerable loss in RX.)
Concordia (CXR) – 1.5% (I expect CXR to be acquired by a larger company.)
Merus Labs (MSL) – 2.2%
Prometic (PLI) – 2.4%
Amgen (AMGN) – 3.1%
Knight (GUD) – 5.1%
I am considering liquidating my holdings in CXR, RX and perhaps MSL and using the proceeds to add to my PLI position and/or an alternative that you might recommend unless you think I am too overweight in this sector.
Thank you for your analysis and recommendations.
With appreciation
Ed
I currently have 14.8% of my investments, excluding real estate and bullion, in the biotech/healthcare sector. I hold
Biosyent (RX) 0.5% (I have a considerable loss in RX.)
Concordia (CXR) – 1.5% (I expect CXR to be acquired by a larger company.)
Merus Labs (MSL) – 2.2%
Prometic (PLI) – 2.4%
Amgen (AMGN) – 3.1%
Knight (GUD) – 5.1%
I am considering liquidating my holdings in CXR, RX and perhaps MSL and using the proceeds to add to my PLI position and/or an alternative that you might recommend unless you think I am too overweight in this sector.
Thank you for your analysis and recommendations.
With appreciation
Ed
Q: Looking to understand the process a bit better. At what point does a board of directors need to disclose that they have been approached about a possible sale? How do they decide whether to go public or to keep confidential? What are the odds a deal is announced this weekend?
Regards,
Robert
Regards,
Robert
Q: I currently own CXR but underwater so would you still recommend this stock a buy with all news happening?
Dolores
Dolores
Q: I would appreciate your thoughts on Merus Labs.
Thanks Richard
Thanks Richard
Q: Why would Concordia agree to enter into discussions with Blackrock (or others) if they have confidence in their ability to integrate recent acquisitions, roll out newly-acquired drugs across a larger geographic area, and generally execute on their business plans? Doesn't it suggest management see insurmountable issues ahead in one or more areas? Thank you for your comments.
Q: Hi Peter and Team,
What is the reasonable take over price for Concordia?
Thanks
What is the reasonable take over price for Concordia?
Thanks
Q: What is the most likely scenario with Cxr tomorrow after it was halted today,do you think it will trading at the opening bell or what has to happen to "unhault " trading have 300 shares and have a nice profit on a quick trade just wandering the best way to sell tomorrow thanks for your great service
Q: Concordia has been acting very poorly for quite some time, especially since their last earnings report. Is it still being associated too much with VRX or is there something else? (i.e management compensation) I do not want to exit my position as this seems so cheap based on forward earnings. I know they have a ton of debt but this should be managed based on their forecasts. Is this just a case of the market being short sighted?
Q: I'm wondering why a trading halt would last for so long when the news is already out, and it's something as benign as preliminary discussions after being approached by another party. Is there something else coming?
Q: Hello Team,
Could you give me your analysis on Allergan. It is down dramatically since the merger with Pfizer was stopped. Is it great value, or a value trap/
Thank You,
Barry
Could you give me your analysis on Allergan. It is down dramatically since the merger with Pfizer was stopped. Is it great value, or a value trap/
Thank You,
Barry
Q: just reading the Annual and Special Meeting of Shareholders and Management Information Circular and noticed that they want to do a Share Consolidation sometime in the future. Is this a good thing as I have often seen the price of the stock decline after doing a stock consolidation?
Thanks
Dolores
Thanks
Dolores
Q: Hello team, How would this news released yesterday (19 April) affect PHM? Worth holding?
Thank you!
...announced today that it has promoted Greg Crawford to the position of Chief Operating Officer.
In finalizing the post-closing payments for the previously announced acquisition of Patient-Aids, PHM and Mr. Crawford have agreed to amend the original purchase agreement which required PHM to pay approximately $11.4 million to Mr. Crawford in a combination of cash and shares over two payments in April and October 2016.
Under the amending agreement, Mr. Crawford has elected to receive all of the remaining consideration due under the original purchase agreement for 33,758,952 shares in addition to stepping into his new role as Chief Operating Officer. As a result, total insider ownership will exceed 20%. In addition, PHM will issue to an arms-length party 285,000 shares associated with the closing of the amendment. The foregoing transactions are subject to final approval of the TSX Venture Exchange.
Thank you!
...announced today that it has promoted Greg Crawford to the position of Chief Operating Officer.
In finalizing the post-closing payments for the previously announced acquisition of Patient-Aids, PHM and Mr. Crawford have agreed to amend the original purchase agreement which required PHM to pay approximately $11.4 million to Mr. Crawford in a combination of cash and shares over two payments in April and October 2016.
Under the amending agreement, Mr. Crawford has elected to receive all of the remaining consideration due under the original purchase agreement for 33,758,952 shares in addition to stepping into his new role as Chief Operating Officer. As a result, total insider ownership will exceed 20%. In addition, PHM will issue to an arms-length party 285,000 shares associated with the closing of the amendment. The foregoing transactions are subject to final approval of the TSX Venture Exchange.
Q: Can you give me your opinion of CRH as a speculative growth stock